Principles of CNS drug development: from test tube to patient
An overview of the major CNS disorders -- Neurobiological correlates of CNS disorders -- Current pharmacological targets -- Premarketing efficacy evaluation -- Pharmacokinetic considerations : absorption, distribution, metabolism, and elimination -- Safety concerns relating to CNS drugs -- Preclinic...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Chichester
Wiley-Blackwell
2009
|
| Ausgabe: | 1. impr. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Zusammenfassung: | An overview of the major CNS disorders -- Neurobiological correlates of CNS disorders -- Current pharmacological targets -- Premarketing efficacy evaluation -- Pharmacokinetic considerations : absorption, distribution, metabolism, and elimination -- Safety concerns relating to CNS drugs -- Preclinical and clinical safety evaluation -- CNS drug targets in development and future perspectives |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | XX, 304 S. graph. Darst. |
| ISBN: | 9780470519790 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV037409170 | ||
| 003 | DE-604 | ||
| 005 | 20110615 | ||
| 007 | t | ||
| 008 | 110519s2009 d||| |||| 00||| eng d | ||
| 010 | |a 2009041400 | ||
| 020 | |a 9780470519790 |9 978-0-470-51979-0 | ||
| 024 | 3 | |a 9780470519790 | |
| 035 | |a (OCoLC)603211195 | ||
| 035 | |a (DE-599)BSZ334836409 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 084 | |a VS 7100 |0 (DE-625)147698:253 |2 rvk | ||
| 100 | 1 | |a Kelly, John |e Verfasser |0 (DE-588)140737200 |4 aut | |
| 245 | 1 | 0 | |a Principles of CNS drug development |b from test tube to patient |c John Kelly |
| 250 | |a 1. impr. | ||
| 264 | 1 | |a Chichester |b Wiley-Blackwell |c 2009 | |
| 300 | |a XX, 304 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 520 | |a An overview of the major CNS disorders -- Neurobiological correlates of CNS disorders -- Current pharmacological targets -- Premarketing efficacy evaluation -- Pharmacokinetic considerations : absorption, distribution, metabolism, and elimination -- Safety concerns relating to CNS drugs -- Preclinical and clinical safety evaluation -- CNS drug targets in development and future perspectives | ||
| 650 | 4 | |a Neuropharmacology | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Central Nervous System Agents | |
| 650 | 4 | |a Central Nervous System Diseases / drug therapy | |
| 650 | 4 | |a Drug Discovery | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022561674&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-022561674 | ||
Datensatz im Suchindex
| _version_ | 1804145705692954624 |
|---|---|
| adam_text | Titel: Principles of CNS drug development
Autor: Kelly, John
Jahr: 2009
Contents
Acknowledgements
Preface
Abbreviations
XI
xiii
xvii
Introduction 1
1.1 The global burden of CNS disease 2
1.2 Assessment of the global burden of disease 3
1.3 The prevalence of CNS disorders 5
1.4 Disability due to CNS disorders 5
1.5 Economic Costs 8
1.6 Concluding comments 11
References 11
An overview of the major CNS disorders 13
2.1 Introduction 13
2.2 Overview of psychiatric disorders 17
2.3 Overview of neurological/neurodegenerative
disorders 31
2.4 Concluding comments 37
References 38
Neurobiological substrates of CNS disorders 43
3.1 Introduction 43
3.2 Brief introduction to the principles of chemical
neurotransmission 44
3.3 Stages of chemical neurotransmission 47
3.4 Approaches to investigating CNS alterations in CNS disorders 50
3.5 Evidence for a neurobiological rationale for CNS disorders 53
3.6 Concluding comments 61
References 62
Current pharmacological targets 65
4.1 Introduction 65
4.2 Pharmacological treatments for depression 67
4.3 Pharmacological treatments for schizophrenia 71
CONTENTS
4.4 Pharmacological treatments for anxiety disorders 75
4.5 Pharmacological treatments for epilepsy 77
4.6 Pharmacological treatments for Parkinson s disease 80
4.7 Pharmacological treatments for Alzheimer s disease 82
4.8 Concluding comments 83
References 84
Premarketing efficacy evaluation 87
5.1 Introduction 87
5.2 Target identification 90
5.3 Lead optimisation 91
5.4 Target validation in animal models 97
5.5 The use of genetically modified animals in CNS drug
development 100
5.6 A selection of animal models of psychiatric disease 101
5.7 A selection of animal models of neurodegenerative disease 108
5.8 Which models to choose 111
5.9 Clinical trials that evaluate drug efficacy 112
5.10 Specific drug profiles 120
References 121
Pharmacokinetic considerations: Absorption, distribution,
metabolism and elimination 127
6.1 Introduction 127
6.2 What are the ideal pharmacokinetic properties for a CNS drug? 129
6.3 Absorption 131
6.4 Distribution 141
6.5 Metabolism 150
6.6 Elimination 158
6.7 Measurement of drug concentrations 160
6.8 Factors that affect pharmacokinetics 161
6.9 Allometric scaling 163
6.10 Microdosing (Phase 0) Studies 163
6.11 Dose prediction and therapeutic drug monitoring 164
6.12 Stereoselectivity of metabolism of drugs 164
6.13 Specific drug profiles 165
6.14 Concluding comments 166
References 166
7 Safety concerns 173
7.1 Introduction 173
7.2 Postmarketing surveillance 174
7.3 Acute poisoning 175
7.4 Quantification of the relative risk of fatalities from CNS drugs 176
7.5 Adverse drug reactions (ADRs) 182
CONTENTS ix
7.6 Specific types of toxicity encountered with psychotropic drugs 183
7.7 Safety concerns following long-term administration of CNS Drugs 185
7.8 Polypharmacy 199
7.9 Specific drug profiles 201
7.10 Concluding comments 203
References 204
Websites 210
8 Preclinical and clinical safety evaluation 211
8.1 Introduction 211
8.2 Preclinical exploratory toxicology and safety pharmacology evaluations 215
8.3 Primary and secondary pharmacology 216
8.4 Safety pharmacology 220
8.5 Toxicology studies required for regulatory purposes 224
8.6 Clinical Studies 238
8.7 Specific drug profiles 239
8.8 Concluding comments 240
References 241
Websites 244
9 CNS drug targets in development and future
perspectives 245
9.1 Introduction 245
9.2 How much does it cost to develop a drug? 247
9.3 Clinical drug development times 248
9.4 Harmonisarion between regulatory agencies 248
9.5 Development of biomarkers for clinical efficacy 249
9.6 Quality of life issues 255
9.7 Cost-effectiveness of novel treatments 257
9.8 Patient advocacy groups 258
9.9 Novel targets for CNS disorders 259
9.10 Targets in selected CNS disorders 261
9.11 Targeting of signalling pathways 270
9.12 Cardiovascular drugs in Alzheimer s disease 273
9.13 Modifying oxidative stress and inflammatory
responses 274
9.14 Targeting of the amyloid-/? protein in Alzheimer s disease 276
9.15 Concluding comments 278
References 279
Appendices 287
Index 295
|
| any_adam_object | 1 |
| author | Kelly, John |
| author_GND | (DE-588)140737200 |
| author_facet | Kelly, John |
| author_role | aut |
| author_sort | Kelly, John |
| author_variant | j k jk |
| building | Verbundindex |
| bvnumber | BV037409170 |
| classification_rvk | VS 7100 |
| ctrlnum | (OCoLC)603211195 (DE-599)BSZ334836409 |
| discipline | Chemie / Pharmazie |
| edition | 1. impr. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01797nam a2200397 c 4500</leader><controlfield tag="001">BV037409170</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20110615 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">110519s2009 d||| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2009041400</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470519790</subfield><subfield code="9">978-0-470-51979-0</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9780470519790</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)603211195</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ334836409</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 7100</subfield><subfield code="0">(DE-625)147698:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kelly, John</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)140737200</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Principles of CNS drug development</subfield><subfield code="b">from test tube to patient</subfield><subfield code="c">John Kelly</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. impr.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Chichester</subfield><subfield code="b">Wiley-Blackwell</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XX, 304 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">An overview of the major CNS disorders -- Neurobiological correlates of CNS disorders -- Current pharmacological targets -- Premarketing efficacy evaluation -- Pharmacokinetic considerations : absorption, distribution, metabolism, and elimination -- Safety concerns relating to CNS drugs -- Preclinical and clinical safety evaluation -- CNS drug targets in development and future perspectives</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuropharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Nervous System Agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Nervous System Diseases / drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Discovery</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022561674&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-022561674</subfield></datafield></record></collection> |
| id | DE-604.BV037409170 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T23:23:42Z |
| institution | BVB |
| isbn | 9780470519790 |
| language | English |
| lccn | 2009041400 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-022561674 |
| oclc_num | 603211195 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | XX, 304 S. graph. Darst. |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | Wiley-Blackwell |
| record_format | marc |
| spelling | Kelly, John Verfasser (DE-588)140737200 aut Principles of CNS drug development from test tube to patient John Kelly 1. impr. Chichester Wiley-Blackwell 2009 XX, 304 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index An overview of the major CNS disorders -- Neurobiological correlates of CNS disorders -- Current pharmacological targets -- Premarketing efficacy evaluation -- Pharmacokinetic considerations : absorption, distribution, metabolism, and elimination -- Safety concerns relating to CNS drugs -- Preclinical and clinical safety evaluation -- CNS drug targets in development and future perspectives Neuropharmacology Drug development Central Nervous System Agents Central Nervous System Diseases / drug therapy Drug Discovery HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022561674&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Kelly, John Principles of CNS drug development from test tube to patient Neuropharmacology Drug development Central Nervous System Agents Central Nervous System Diseases / drug therapy Drug Discovery |
| title | Principles of CNS drug development from test tube to patient |
| title_auth | Principles of CNS drug development from test tube to patient |
| title_exact_search | Principles of CNS drug development from test tube to patient |
| title_full | Principles of CNS drug development from test tube to patient John Kelly |
| title_fullStr | Principles of CNS drug development from test tube to patient John Kelly |
| title_full_unstemmed | Principles of CNS drug development from test tube to patient John Kelly |
| title_short | Principles of CNS drug development |
| title_sort | principles of cns drug development from test tube to patient |
| title_sub | from test tube to patient |
| topic | Neuropharmacology Drug development Central Nervous System Agents Central Nervous System Diseases / drug therapy Drug Discovery |
| topic_facet | Neuropharmacology Drug development Central Nervous System Agents Central Nervous System Diseases / drug therapy Drug Discovery |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=022561674&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT kellyjohn principlesofcnsdrugdevelopmentfromtesttubetopatient |